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Cytokine responses to Staphylococcus aureus
bloodstream infection differ between patient
cohorts that have different clinical courses of
infection
Sinead McNicholas1, Alida Fe Talento2, Joanne O’Gorman3, Margaret M Hannan3, Maureen Lynch3,
Catherine M Greene4, Hilary Humphreys1,2 and Deirdre Fitzgerald-Hughes1*
Abstract
Background: The clinical course of Staphylococcus aureus bloodstream infection is unpredictable and bacterial
virulence, host immune response and patient characteristics are among the factors that contribute to the clinical
course of infection. To investigate the relationship between cytokine response and clinical outcome, circulating
cytokine levels were investigated in response to S. aureus bloodstream infection in patients with different clinical
courses of infection.
Methods: A prospective study was carried out in 61 patients with S. aureus bloodstream infection and circulating
levels of IL-6, GRO-γ, RANTES and leptin were assessed over the course of the infection. Levels were compared in
patients with complicated courses of infection (e.g. infective endocarditis) versus uncomplicated courses of S. aureus
bloodstream infection and methicillin-resistant S. aureus Vs methicillin-susceptible S. aureus infection.
Results: Significantly lower leptin levels (p < 0.05) and significantly higher IL-6 levels (p < 0.05) were detected at
laboratory diagnosis in patients with complicated compared to uncomplicated S. aureus bloodstream infection.
Significantly higher levels of GRO-γ were associated with MRSA infection compared to MSSA infection.
Conclusions: IL-6 may be an early inflammatory marker of complicated S. aureus bloodstream infection. Leptin may
be protective against the development of a complicated S. aureus bloodstream infection.
Keywords: Staphylococcus aureus, Bloodstream infection, Pro inflammatory cytokine, Renal impairment, Haemodialysis,
Immune mediator, Leptin, RANTES, IL-6
Background
Staphylococcus aureus bloodstream infection (SABSI) is
one of the most severe manifestations of S. aureus with an
estimated mortality rate of 20% [1]. However, the outcome
of SABSI is variable. Many patients develop uncompli-
cated resolving infections that respond to appropriate
antimicrobial therapy while others develop persistent or
complicated infection with metastatic foci (e.g. infective
endocarditis (IE)), which may be fatal. Factors that con-
tribute to the clinical outcome of SABSI, include the
virulence and antibiotic susceptibility of the infecting
isolate [2,3], host innate and humoral immune responses
[4,5] and the underlying condition of the patient [6]. S.
aureus molecules such as peptidoglycan and lipoteichoic
acid (LTA) are potential stimulators of cytokine produc-
tion (e.g. TNF-α, IL-1β, IL-6, IL-4, IL-8, IFN-γ and IL-12),
in response to infection [7] but un-regulated cytokine pro-
duction may contribute to S. aureus pathogenesis. Differ-
ential cytokine responses to S. aureus may contribute to
varying clinical outcomes of SABSI. This prospective study
aimed to; identify cytokines or chemokines that are im-
portant in the immune response to SABSI, determine the
levels of these molecules in sequential plasma samples
taken over the course of SABSI and investigate these
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cytokine responses in SABSI with a complicated clinical
course versus an uncomplicated course and those with
MRSA infection compared to those with MSSA infection.
Methods
Setting, patients and definitions
Blood samples were collected from patients with SABSI in
Beaumont Hospital (BH), from October 2008 to February
2011 and in the Mater Misericordiae University Hospital
(MMUH) from November 2009 to March 2010. Both
are >500-bed tertiary referral centres, located in Dublin,
Ireland. BH is the national centre for renal and pancreatic
transplantation, neurosurgery and cochlear implantation.
The MMUH has the largest cardiothoracic surgical de-
partment in the country and is the national centre for
heart and lung transplantation. Approval from BH and
MMUH Ethics Committees was received. Participation
was by informed consent/assent from patients/relatives.
Patient demographics, including age, sex, co-morbidities,
timing of onset of SABSI, source of SABSI, isolate anti-
microbial susceptibility and infection outcomes were col-
lected prospectively from patient’s charts, nursing notes
and microbiological records. Plasma samples were prepared
from blood collected on the day of the laboratory diagnosis
of SABSI, seven days later and in patients with complicated
infection, on day 14 after laboratory-confirmed diagnosis.
Plasma was also prepared from the blood of four healthy
control individuals. An uncomplicated course of infection
was defined specifically for this study as follows; negative
follow-up blood culture, subsidence of fever within 72 h,
normal findings on transesophageal echocardiogram and
no symptoms suggestive of metastatic infection. A compli-
cated course of infection was defined specifically for this
study as; positive follow up blood culture, despite at least
three days of appropriate antibiotics (e.g. flucloxacillin for
methicillin-susceptible S. aureus (MSSA), vancomycin for
methicillin-resistant S. aureus (MRSA)), disseminated infec-
tion such as osteomyelitis, or IE. Nosocomial, healthcare-
associated and community-acquired infection were defined
as described by Friedman et al. [8].
Preliminary identification of cytokines in plasma from
patients with SABSI using a panel of pro-inflammatory
cytokines
A commercially available antibody based cytokine/
chemokine microarray (RayBio® Human Cytokine Anti-
body Array 3 (RayBiotech Inc., GA, USA)) was used to
identify cytokines that were differentially expressed in
pooled plasma (taken on the day of diagnosis) from
three patients with uncomplicated BSI and three with
complicated BSI. Pooled plasma was used for the prelimin-
ary screen only, to minimise resources required. The panel
consists of antibodies against 42 pro-inflammatory cyto-
kines and chemokines and the manufacturer’s instructions
were followed. Cytokine signal intensities were captured
and quantified by the chemiluminescence imaging sys-
tem G:BOX Chemi XL (Syngene UK, Cambridge, UK).
Mean values for each cytokine were expressed relative
to the mean positive value for each array membrane
(mean of 6 positive control spots per membrane). A
change in cytokine levels in pooled plasma, at a ratio
threshold of at least 1.4 fold between groups was con-
sidered to be potentially relevant and the results from
this preliminary screen influenced the decision on which
cytokines to investigate in individual patients over the
course of their infection.
Enzyme-linked immunosorbant assay (ELISA)
The levels of IL-6, GRO-γ, RANTES and leptin were de-
termined in patient and healthy donor plasma samples
using immunometric sandwich ELISA (R and D systems,
Abington, UK (IL-6, RANTES, leptin) or Acris Antibodies
Ltd, Germany (GRO-γ). The manufacturer’s instructions
were followed using 50–100 μl of plasma. Plasma protein
concentrations were measured using the Bradford assay
and cytokine levels were normalised to plasma protein
concentration to account for variability in blood process-
ing and biological variations in plasma protein concentra-
tions between patients, many of whom were undergoing
haemodialysis.
Statistical analysis
Unpaired t-tests were used to compare the means of
data sets. Fisher’s exact test was used to compare cat-
egorical data. Graphpad Prism 4 was used for Statistical
analyses.
Results
Patient details
In total, 61 patients were studied, 15 (24.5%) with MRSA
BSI, 46 (75.4%) with MSSA BSI. Fifty (82%) patients had
an uncomplicated BSI and 11 (18%) had a complicated
course of SABSI as defined for this study. Detailed pa-
tient demographics are shown in Table 1. Two patients
died and SABSI was identified as the cause in one of
these (complicated, IE). A high rate of IE was found
among those with complicated SABSI (8/11, 73%) and
most complicated SABSI was healthcare-associated (7/
11, 64%). Of the 15 patients with MRSA infection, four
had a complicated clinical course and an increased risk
of complications was not identified in those with MRSA
Vs MSSA (4/15, 26% Vs, 11/46 (24%), RR1.1).
Identification of cytokines for further investigation in
complicated or uncomplicated SABSI
A panel of 42 cytokine antibodies were probed by hybri-
dization of pooled plasma taken on the day of diagnosis,
from three patients with complicated SABSI and three
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with uncomplicated SABSI. The position and name of
each of the 42 cytokine antibodies on the array is shown
on the cytokine antibody array map (Figure 1A). An image
of the resulting hybridisation patterns for representative
pooled samples from each group is shown in Figure 1B
and cytokines that showed ≥1.4 fold differences in levels
between groups are highlighted. These cytokines; IL-6,
GRO-γ and RANTES (Regulated upon Activation, Normal
T-cell Expressed, and Secreted) were identified for further
study. Leptin levels were marginally lower in pooled
plasma from patients with complicated SABSI compared
to uncomplicated but this cytokine was further studied be-
cause its levels were increased >2-fold in pooled plasma
from three patients with MRSA compared to MSSA BSI
(Figure 1C).
Further investigation of these four cytokines in all pa-
tients with SABSI, using individual ELISAs revealed
inter-patient variability in cytokine levels. However, the
mean cytokine levels varied over the course of SABSI
(Figure 2). Mean IL-6 and GRO-γ levels decreased over
the course of infection, and the decrease was statistically
significant in the case of IL-6 (p ≤ 0.05). Mean RANTES
levels were increased seven days following laboratory
diagnosis compared to levels on the day of laboratory
diagnosis of SABSI (p ≤ 0.0001). Further samples were
taken 14 days following SABSI diagnosis only from pa-
tients with complicated SABSI (n = 11) and were there-
fore not included in these analyses.
Cytokine levels and the clinical outcome of SABSI
The mean cytokine levels found in patients with compli-
cated SABSI Vs uncomplicated SABSI are shown in Figure 3.
Those with complicated SABSI had significantly higher
mean IL-6 levels compared to those with uncomplicated
SABSI on the day of diagnosis (p ≤ 0.05) (Figure 3, panel A).
Mean GRO-γ levels were greater in patients with com-
plicated SABSI compared to uncomplicated SABSI but
these differences were not statistically significant (Figure 3,
panel B). Mean RANTES (Figure 3, panel C) levels were sig-
nificantly higher on day seven following diagnosis of SABSI
compared to those found on the day of diagnosis in patients
with uncomplicated (p ≤ 0.0001) and complicated SABSI
(p ≤ 0.05). Leptin levels (Figure 3, panel D) were significantly
reduced in patients with complicated SABSI compared to
patients with uncomplicated SABSI on the day of diagnosis
(p ≤ 0.05). Mean levels of IL-6, GRO-γ and RANTES values
in healthy individuals were lower than those in patients with
complicated and uncomplicated SABSI on the day of diag-
nosis and seven days later. Mean leptin levels, although
lower in healthy individuals than those with uncomplicated
SABSI, were raised in healthy individuals compared to those
with complicated infection (Figure 3).
Cytokine responses SABSI caused by MSSA Vs MRSA
The mean levels of GRO-γ were significantly greater in
patient with SABSI in cases where an MRSA was the
source of infection (p ≤ 0.05) but this increase was only
evident when comparing the samples taken on the day
of diagnosis (Figure 4). The mean level of the other three
cytokines investigated, were not significantly altered in
patients with SABSI caused by MRSA Vs MSSA (data
not shown).
Table 1 Characteristics of 61 patients with S. aureus
bloodstream infection (BSI)
Patient characteristic No. of patient (%)
Gender
Male 38 (62.3)
Female 23 (37.7)
Age
>65 35 (57.38)
<65 26 (42.63)
Co-morbiditiesa
Cardiac disease 22 (36.07)
bRenal impairment 23 (37.70)
Diabetes mellitus 16 (26.23)
Chronic obstructive pulmonary disease 8 (13.11)
Autoimmune disease 6 (9.84)
Onset of BSIc
Nosocomial 31 (50.82)
Healthcare-associated 22 (36.07)
Community-acquired 8 (13.11)
Source of BSI
Unknown 15 (24.6)
Prosthetic device 30 (49.18)
Other 16 (26.23)
Susceptibility of infecting isolate
Methicillin-susceptible S. aureus 46 (75.41)
Methicillin-resistant S. aureus 15 (24.59)
Outcome of BSI
Uncomplicated BSI 50 (81.96)
Complicated BSI 11 (18.03)
Death 2 (3.28)
Type of complication
Infective endocarditis 8 (13.11)
Persistently positive blood culture 1 (1.64)
Septic arthritis 1 (1.64)
Discitis 1 (1.64)
aMore than one co-morbidity was indentified in some patients. bOf 23 patients
with renal impairment, 21 were on haemodialysis (HD), one had chronic renal failure
but was not on HD and one was receiving plasmaphoresis for Waldenströms
macroglobulinaemia. cOnset of BSI defined as described by Friedman et al., 2002 [8].
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Discussion
Pro-inflammatory cytokines released in response to S.
aureus infection may contribute to the cascade of events
that lead to severe complications in SABSI [9]. Cytokines
including IL-6, GRO-γ and RANTES are up-regulated in
response to S. aureus clinical isolates in epithelial cell in-
fection models [10,11]. We observed changes in the cir-
culating levels of these cytokines in patients over the
course of SABSI. In addition, greater circulating IL-6
levels and reduced leptin levels were observed in compli-
cated SABSI compared to uncomplicated SABSI. Com-
plicated infection was defined specifically for this study
as described above and IE was the predominant compli-
cation. The surprisingly high rate of IE (8/61, 13%) may
be partly explained by our policy of echocardiograms for
all patients with SABSI regardless of the response to
therapy and the presence of a national centre for cardiac
and lung transplantation in one of the study hospitals. In
addition, an increased circulating level of GRO-γ was
noted in response to MRSA Vs MSSA bloodstream
infection.
The cytokine response to sepsis has been well docu-
mented, with IL-6 suggested as an early marker and a
marker of severity [12-15]. The cytokine response in
A
B C
Figure 1 Analysis of differential cytokine levels in pooled plasma from patients with SABSI. The cytokine antibody array map (RayBiotech
Inc., GA) showing the positions of 42 duplicate cytokines, positive and negative controls (A). Hybridization patterns for pooled plasma from three
patients per group, comparing patients with complicated SABSI to patients with uncomplicated SABSI (B) and patients with MSSA to patients
with MRSA (C). Arrows indicate cytokines selected for investigation in all patients (B and C) and were based on a fold change in levels of ≥1.4
between groups. Fold change was estimated from cytokine signal intensity from compared groups (uncomplicated/complicated, MSSA/MRSA)
where signal intensity was normalised with respect to the signal intensity of six positive control spots on each membrane, located at positions
A1, A2, B1, B2, L7, L8.
Figure 2 Scatter plot of the concentrations of four cytokines in
all patient samples collected over the course of S. aureus BSI.
Cytokine levels on the day of laboratory diagnosis and seven days
after diagnosis of SABSI are shown (n = 61). Horizontal bars show the
mean values for each cytokine.
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SABSI also appears to involve IL-6 elevation early in the
course of infection although the levels were lower than
those reported in Gram-positive sepsis [16]. An earlier
study suggested that IL-6 levels decay more rapidly in
sepsis survivors than in non-survivors over a 96 h period
supporting its prognostic value [17]. However, in the
present study on SABSI, where cytokines were assessed
over a longer period, IL-6 levels decreased to similar
levels in complicated and uncomplicated SABSI by day
seven following laboratory diagnosis. Nonetheless, a sig-
nificantly elevated IL-6 level on the day of diagnosis of
SABSI appears to correlate with a poorer prognosis.
In-vitro studies have shown increased RANTES levels in
epithelial cells exposed to S. aureus clinical isolates [11].
However, a role for RANTES in the immune response to
SABSI has not been previously reported. RANTES’ main
function is as a chemotactic agent for leucocytes facilitat-
ing their recruitment to infection sites [18]. RANTES pro-
duction is thought to be induced by TNF-α and IL-1α,
both of which are produced in response to S. aureus com-
ponents (e.g. peptidoglycan, LTA) [19,20]. Our observation
of a significant rise in RANTES levels in all patient groups
by day seven, suggests that RANTES production is stimu-
lated by S. aureus in vivo and it may have a functional role
in the immune response to this pathogen. It appears that
once produced, circulating RANTES levels remain high.
Furthermore, mean levels remained elevated in those with
complicated SABSI up to 14 days following diagnosis. The
purpose of this persistence is not clear but it may reflect
the ongoing response to persistent SABSI.
Leptin levels were significantly higher in uncompli-
cated versus complicated SABSI on the day of laboratory
diagnosis (p ≤ 0.05) and a similar trend was identified on
day seven following diagnosis (p = 0.071), indicating that
patients with more severe infection had a sustained at-
tenuated leptin response. Leptin is reported to have both
beneficial and detrimental effects for the host in the set-
ting of sepsis. It stimulates proliferation of lymphohae-
matopoetic cells and increases the phagocytic activity of
macrophages which may enhance host eradication of S.
aureus but it can also activate endothelial cells resulting
in a severe sepsis phenotype [21,22]. Both negative and
Figure 3 Cytokine levels in patients with uncomplicated Vs complicated SABSI. Cytokine levels in plasma from patients with uncomplicated
(clear bars, n = 50) and complicated (solid grey bars, n = 11) SABSI at diagnosis (day 0), day 7 and day 14. Data shown represent mean cytokine
concentration ± SEM for IL-6 (A), GRO-γ (B), RANTES (C) and leptin (D). Dotted lines in each panel indicate the mean cytokine levels found in four
healthy control individuals.
Figure 4 Scatter plot of GRO-γ levels in patients with SABSI
caused by MRSA Vs SABSI caused by MSSA. GRO-γ levels in
patients with MSSA (open circles, n = 46) or MRSA BSI (closed circles,
n = 15) over the course of SABSI. Horizontal bars show the mean
values for each cytokine.
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positive correlations between leptin levels and clinical out-
come in patients with sepsis have been reported [22,23].
The present study supports the suggestion that higher lep-
tin levels are protective. Decreased leptin levels in patients
with complicated infection may contribute to poor clinical
outcome by reducing the host’s ability to eradicate the in-
fection. These findings support the possibility that admin-
istration of leptin may benefit patients with severe SABSI
as one animal study reported that exogenous administra-
tion of leptin reduced the severity of S. aureus-induced
septic arthritis in two mouse models [24].
We did not find evidence that GRO-γ levels were altered
in patients with a complicated course of infection. How-
ever, our data suggest that this cytokine may play a role in
the response to MRSA infection specifically. The cause
and clinical implications of this finding are unclear. Bac-
terial components, such as peptidoglycan and LTA that
stimulate GRO-γ production via IL-1 and TNF-α [20] are
common to MRSA and MSSA. Furthermore, the chemo-
attractant properties of GRO-γ are equally important in
MRSA and MSSA (BSI). It has been shown that mecA
augments the expression of virulence genes such as fnb
[25] and increased expression of α-toxin and phenol sol-
uble modulin has been shown in community-acquired
MRSA [26]. It is therefore possible that differential host
immune responses such as increased GRO-γ production
may result indirectly from increased expression of viru-
lence genes in MRSA.
There were limitations to this study. Despite extension
to two centres, only 61 patients were recruited over
28 months, providing a relatively small study size. There
were logistical issues related to obtaining samples from very
ill patients or the movement or discharge of patients before
samples could be taken. Samples at 14 days after diagnosis
were only taken from inpatients with complicated SABSI
and not those discharged by this time. Moreover, a true
baseline cytokine level was not obtained as this would
require screening large numbers of patients before the de-
velopment and laboratory diagnosis of SABSI. Complicated
SABSI was under-represented because of the difficulty
obtaining patient consent or assent from relatives of very ill
or rapidly deteriorating patients. The contribution of co-
morbid conditions associated with SABSI (e.g. concurrent
infection, autoimmune conditions, recent surgery etc.)
which was not part of this study, to the cytokine response
cannot be excluded. Finally, the first blood sample was
taken on the day of laboratory diagnosis of SABSI and not
when SABSI was first suspected on clinical grounds. This
time difference was variable but may have been at least two
days, over which cytokine levels may have changed.
Conclusions
In conclusion, differential expression of certain cytokines,
such as IL-6 and leptin occurs in patients with different
clinical courses of SABSI. While acknowledging that fur-
ther studies on larger patient groups are required, these
cytokines may be considered as potential prognostic
markers or potentially be modified to minimise the adverse
effects of S. aureus infection in vulnerable patients. Add-
itionally, the increased expression of RANTES in all groups
over the course of SABSI suggests that it may play a novel
role in response to this pathogen.
Abbreviations
SABSI: Staphylococcus aureus bloodstream infection; RANTES: Regulated upon
activation, normal T-cell expressed; GRO: Growth regulated oncogene;
IE: Infective endocarditis; MRSA: Methicillin-resistant S. aureus;
MSSA: Methicillin-susceptible S. aureus; TNF: Tumour necrosis factor;
IL: Interleukin; IFN: Interferon; LTA: Lipoteichoic acid; ELISA: Enzyme linked
immunosorbant assay; BH: Beaumont Hospital; MMUH: Mater Misericordiae
University Hospital.
Competing interests
HH has received research support from Steris Corporation, Inov8 Science,
Pfizer & Cepheid in recent years. He has also recently received lecture &
other fees from Novartis, Astellas and AstraZeneca. No conflict of interest is
reported by the other co-authors.
Authors’ contributions
SMN participated in the conduct of the experiments described and
produced the first draft. AT and JO’G participated in patient recruitment and
sample collection, MH and ML facilitated the study, guided the ethics
application at MMUH and provided critical appraisal of the manuscript, CG
participated in data analysis and interpretation of the data and provided
critical appraisal of the manuscript. HH and DFH conceived of the study, DH
directed the experimental work and redrafted the manuscript. All authors
approved the final manuscript.
Acknowledgments
This work was supported by Pfizer Ireland [Educational Award, No.WS 376235].
Author details
1Department of Clinical Microbiology, RCSI Education and Research Centre,
Beaumont Hospital, Dublin 9, Ireland. 2Department of Microbiology,
Beaumont Hospital, Dublin, Ireland. 3Department of Microbiology, Mater
Misericordiae University Hospital, Dublin, Ireland. 4Department of Medicine,
Royal College of Surgeons in Ireland, Dublin, Ireland.
Received: 26 November 2013 Accepted: 22 October 2014
References
1. Lindsay JA, Holden MT: Understanding the rise of the superbug:
investigation of the evolution and genomic variation of Staphylococcus
aureus. Funct Integr Genomics 2006, 6(3):186–201.
2. Fowler VG Jr, Nelson CL, McIntyre LM, Kreiswirth BN, Monk A, Archer GL,
Federspiel J, Naidich S, Remortel B, Rude T, Brown P, Reller LB, Corey GR,
Gill SR: Potential associations between hematogenous complications and
bacterial genotype in Staphylococcus aureus infection. J Infect Dis 2007,
196(5):738–747.
3. Takata T, Miyazaki M, Futo M, Hara S, Shiotsuka S, Kamimura H, Yoshimura H,
Matsunaga A, Nishida T, Ishikura H, Tamura K, Tsuji BT: Presence of both
heterogeneous vancomycin-intermediate resistance and beta-lactam
antibiotic-induced vancomycin resistance phenotypes is associated with
the outcome in methicillin-resistant Staphylococcus aureus bloodstream
infection. Scand J Infect Dis 2013, 45(3):203–212.
4. Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C, Bes M,
Vandenesch F, Tazir M, Hooijkaas H, Verbrugh HA, van Belkum A, Etienne J,
Lina G, Ramdani-Bouguessa N, van Wamel WJ: Immunogenicity of toxins
during Staphylococcus aureus infection. Clin Infect Dis 2010, 50(1):61–68.
5. Santos SS, Brunialti MK, Rigato O, Machado FR, Silva E, Salomao R:
Generation of nitric oxide and reactive oxygen species by neutrophils
McNicholas et al. BMC Infectious Diseases 2014, 14:580 Page 6 of 7
http://www.biomedcentral.com/1471-2334/14/580
and monocytes from septic patients and association with outcomes.
Shock 2012, 38(1):18–23.
6. Fowler VJ, Justice A, Moore C, Benjamin DK Jr, Woods CW, Campbell S,
Reller LB, Corey GR, Day NP, Peacock SJ: Risk factors for hematogenous
complications of intravascular catheter-associated Staphylococcus aureus
bacteremia. Clin Infect Dis 2005, 40(5):695–703.
7. Wang JE, Jorgensen PF, Almlof M, Thiemermann C, Foster SJ, Aasen AO,
Solberg R: Peptidoglycan and lipoteichoic acid from Staphylococcus
aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10
production in both T cells and monocytes in a human whole blood
model. Infect Immun 2000, 68(7):3965–3970.
8. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W,
Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ: Health
care-associated bloodstream infections in adults: a reason to change the
accepted definition of community-acquired infections. Ann Intern Med
2002, 137(10):791–797.
9. Peres AG, Madrenas J: The broad landscape of immune interactions with
Staphylococcus aureus: from commensalism to lethal infections. Burns
2013, 39(3):380–388.
10. Yao L, Bengualid V, Lowy FD, Gibbons JJ, Hatcher VB, Berman JW:
Internalization of Staphylococcus aureus by endothelial cells induces
cytokine gene expression. Infect Immun 1995, 63(5):1835–1839.
11. Strindhall J, Lindgren PE, Lofgren S, Kihlstrom E: Clinical isolates of
Staphylococcus aureus vary in ability to stimulate cytokine expression in
human endothelial cells. Scand J Immunol 2005, 61(1):57–62.
12. Berbari E, Mabry T, Tsaras G, Spangehl M, Erwin PJ, Murad MH, Steckelberg
J, Osmon D: Inflammatory blood laboratory levels as markers of
prosthetic joint infection: a systematic review and meta-analysis. J Bone
Joint Surg 2010, 92(11):2102–2109.
13. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M:
Cytokine serum level during severe sepsis in human IL-6 as a marker of
severity. Ann Surg 1992, 215(4):356–362.
14. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ,
Eerenberg-Belmer AJ, Thijs LG, Aarden LA: Increased plasma levels of
interleukin-6 in sepsis. Blood 1989, 74(5):1704–1710.
15. Uusitalo-Seppala R, Koskinen P, Leino A, Peuravuori H, Vahlberg T, Rintala
EM: Early detection of severe sepsis in the emergency room: diagnostic
value of plasma C-reactive protein, procalcitonin, and interleukin-6.
Scand J Infect Dis 2011, 43(11–12):883–890.
16. Feezor RJ, Oberholzer C, Baker HV, Novick D, Rubinstein M, Moldawer LL,
Pribble J, Souza S, Dinarello CA, Ertel W, Oberholzer A: Molecular
characterization of the acute inflammatory response to infections with
gram-negative versus gram-positive bacteria. Infect Immun 2003,
71(10):5803–5813.
17. Jekarl DW, Lee SY, Lee J, Park YJ, Kim Y, Park JH, Wee JH, Choi SP:
Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for
sepsis. Diagn Microbiol Infect Dis 2013, 75(4):342–347.
18. Venge J, Lampinen M, Hakansson L, Rak S, Venge P: Identification of IL-5
and RANTES as the major eosinophil chemoattractants in the asthmatic
lung. J Allergy Clin Immunol 1996, 97(5):1110–1115.
19. Megyeri K, Mandi Y, Degre M, Rosztoczy I: Induction of cytokine
production by different Staphylococcal strains. Cytokine 2002,
19(4):206–212.
20. Kanangat S, Postlethwaite A, Cholera S, Williams L, Schaberg D:Modulation of
virulence gene expression in Staphylococcus aureus by interleukin-1beta:
novel implications in bacterial pathogenesis. Microbes Infect 2007, 9(3):408–415.
21. Arnalich F, Lopez J, Codoceo R, Jimnez M, Madero R, Montiel C:
Relationship of plasma leptin to plasma cytokines and human survivalin
sepsis and septic shock. J Infect Dis 1999, 180(3):908–911.
22. Bornstein SR, Licinio J, Tauchnitz R, Engelmann L, Negrao AB, Gold P,
Chrousos GP: Plasma leptin levels are increased in survivors of acute
sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion.
J Clin Endocrinol Metab 1998, 83(1):280–283.
23. Shapiro NI, Khankin EV, Van Meurs M, Shih SC, Lu S, Yano M, Castro PR,
Maratos-Flier E, Parikh SM, Karumanchi SA, Yano K: Leptin exacerbates
sepsis-mediated morbidity and mortality. J Immunol 2010, 185(1):517–524.
24. Hultgren OH, Tarkowski A: Leptin in septic arthritis: decreased levels
during infection and amelioration of disease activity upon its
administration. Arthritis Res 2001, 3(6):389–394.
25. Vaudaux PE, Monzillo V, Francois P, Lew DP, Foster TJ, Berger-Bachi B:
Introduction of the mec element (methicillin resistance) into Staphylococcus
aureus alters in vitro functional activities of fibrinogen and fibronectin
adhesins. Antimicrob Agents Chemother 1998, 42(3):564–570.
26. Otto M: Basis of virulence in community-associated methicillin-resistant
Staphylococcus aureus. Annu Rev Microbiol 2010, 64:143–162.
doi:10.1186/s12879-014-0580-6
Cite this article as: McNicholas et al.: Cytokine responses to
Staphylococcus aureus bloodstream infection differ between patient
cohorts that have different clinical courses of infection. BMC Infectious
Diseases 2014 14:580.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
McNicholas et al. BMC Infectious Diseases 2014, 14:580 Page 7 of 7
http://www.biomedcentral.com/1471-2334/14/580
